UCB-J is a positron emission tomography (PET) radioligand for the synaptic vesicle protein 2A (SV2A).
性状
Solid
体内研究(In Vivo)
UCB-J exhibits high free fraction (0.46 ± 0.02) and metabolizes at a moderate rate (39% ± 5% and 24% ± 3% parent remaining at 30 and 90 min) in plasma.
UCB-J displays high uptake and fast kinetics in the monkey brain.
When the animal is pretreated with UCB-J (150 μg/kg, iv), the whole brain SUV decreases to the same level as centrum semiovale, indicating the in vivo binding specificity of [F]7 to SV2A. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
ClinicalTrial
参考文献
[1]. Jo?l Mercier, et al. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands. ChemMedChem. 2014 Apr;9(4):693-8.[2]. Aline Delva, et al. Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinsons Disease. Mov Disord. 2020 Aug 7.
溶解度数据
In Vitro: DMSO : 100 mg/mL (312.20 mM; Need ultrasonic)配制储备液
[1]. Jo?l Mercier, et al. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands. ChemMedChem. 2014 Apr;9(4):693-8.[2]. Aline Delva, et al. Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinsons Disease. Mov Disord. 2020 Aug 7.